Article

The effect of group music therapy on mood, speech, and singing in individuals with Parkinson's disease--a feasibility study.

Grieg Academy, University of Bergen, Bergen, Norway.
Journal of music therapy (Impact Factor: 0.8). 09/2012; 49(3):278-302. DOI: 10.1093/jmt/49.3.278
Source: PubMed

ABSTRACT Parkinson's disease (PD) is a progressive neurodegenerative disorder where patients exhibit impairments in speech production. Few studies have investigated the influence of music interventions on vocal abilities of individuals with PD.
To evaluate the influence of a group voice and singing intervention on speech, singing, and depressive symptoms in individuals with PD.
Ten patients diagnosed with PD participated in this one-group, repeated measures design study. Participants received the sixty-minute intervention, in a small group setting once a week for 20 consecutive weeks. Speech and singing quality were acoustically analyzed using a KayPentax Multi-Dimensional Voice Program, voice ability using the Voice Handicap Index (VHI), and depressive symptoms using the Montgomery and Asberg Depression rating scale (MADRS). Measures were taken at baseline (Time 1), after 10 weeks of weekly sessions (Time 2), and after 20 weeks of weekly sessions (Time 3).
Significant changes were observed for five of the six singing quality outcomes at Time 2 and 3, as well as voice range and the VHI physical subscale at Time 3. No significant changes were found for speaking quality or depressive symptom outcomes; however, there was an absence of decline on speaking quality outcomes over the intervention period.
Significant improvements in singing quality and voice range, coupled with the absence of decline in speaking quality support group singing as a promising intervention for persons with PD. A two-group randomized control study is needed to determine whether the intervention contributes to maintenance of speaking quality in persons with PD.

7 Followers
 · 
349 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson disease (PD) is a complex, progressive, neurodegenerative disorder that leads to a wide range of deficits including fine and gross sensorimotor impairment, autonomic dysfunction, mood disorders, and cognitive decline. Traditionally, the focus for diagnosis and treatment has been on sensorimotor impairment related to dopamine depletion. It is now widely recognized, however, that PD-related pathology affects multiple central nervous system neurotransmitters and pathways. Communication and swallowing functions can be impaired even in the early stages, significantly affecting health and quality of life. The purpose of this article is to review the literature on early intervention for communication and swallowing impairment in PD. Overarching themes were that (1) studies and interpretation of data from studies in early PD are limited; (2) best therapy practices have not been established, in part due to the heterogeneous nature of PD; and (3) as communication and swallowing problems are pervasive in PD, further treatment research is essential.
    Seminars in Speech and Language 08/2013; 34(3):185-202. DOI:10.1055/s-0033-1358367
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic pain management typically consists of prescription medications or provider-based, behavioral, or interventional procedures which are often ineffective, may be costly, and can be associated with undesirable side effects. Because chronic pain affects the whole person (body, mind, and spirit), patient-centered complementary and integrative medicine (CIM) therapies that acknowledge the patients' roles in their own healing processes have the potential to provide more efficient and comprehensive chronic pain management. Active self-care CIM therapies (ACT-CIM) allow for a more diverse, patient-centered treatment of complex symptoms, promote self-management, and are relatively safe and cost-effective. To date, there are no systematic reviews examining the full range of ACT-CIM used for chronic pain symptom management. A systematic review was conducted, using Samueli Institute's rapid evidence assessment of the literature methodology, to rigorously assess both the quality of the research on ACT-CIM modalities and the evidence for their efficacy and effectiveness in treating chronic pain symptoms. A working group of subject matter experts was also convened to evaluate the overall literature pool and develop recommendations for the use and implementation of these modalities. Following key database searches, 146 randomized controlled trials were included in the review, eight of which investigated sensory art therapies, as defined by the authors. This article summarizes the current evidence, quality, efficacy, and safety of these modalities. Recommendations and next steps to move this field of research forward are also discussed. The entire scope of the review is detailed throughout the current Pain Medicine supplement.
    Pain Medicine 04/2014; 15 Suppl S1:S66-S75. DOI:10.1111/pme.12409 · 2.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study analyzed temporal voice therapy data (duration and frequency) as reported in the scientific literature between 1975 and May 2013. A PubMed search was conducted using the keywords "voice and therapy" and "therapy and dysphonia," resulting in 93 qualified publications. This information was complemented by data reported in scientific textbooks (47 publications). The results show that voice therapy lasts an average of 9.25 weeks distributed over 10.87 sessions of mostly 30 (36.36%) or 60 minutes (27.27%) and occurs once (34.55%) or twice (28.18%) per week. The total amount of time that a voice therapist spends face-to-face with the patient is 8.17 hours on average. Substantial geographic differences are observed, but only data from North America and Europe are sufficiently represented. For North American patients, more sessions (12.52) are reported over a shorter period (7.62 weeks), resulting in more face-to-face time (12.15 hours) between therapist and patient. However, the opposite trend is true for European patients, who average 10.99 sessions over 10.12 weeks, resulting in 7.68 hours of face-to-face time. The potential impact of diagnosis, clinical practices, prescription habits, health insurance rules, patient compliance, and study design on the representativeness of the data is discussed. These results offer a frame of reference regarding international practices for temporal variables in voice therapy that may be useful when identifying voice therapy dosage and optimal practice. Copyright © 2015 The Voice Foundation. Published by Elsevier Inc. All rights reserved.
    03/2015; DOI:10.1016/j.jvoice.2014.12.001